{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T20:18:34Z","timestamp":1788034714913,"version":"build-2784847793"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006044","name":"Astellas Pharma Europe Ltd","doi-asserted-by":"publisher","award":["ISR004823\/BE-72-RG-13"],"award-info":[{"award-number":["ISR004823\/BE-72-RG-13"]}],"id":[{"id":"10.13039\/501100006044","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007659","name":"Bayer Healthcare LLC","doi-asserted-by":"publisher","award":["IIR ISCS 17739"],"award-info":[{"award-number":["IIR ISCS 17739"]}],"id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.euo.2026.08.001","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:30:04Z","timestamp":1787949004000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Alkaline Phosphatase and Prostate-specific Antigen Response in Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide Alone or in Combination with Radium-223: Ad Hoc Analysis of the PEACE-3 Consortium Trial"],"prefix":"10.1016","author":[{"given":"Andrey","family":"Soares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananya","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohann","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond S.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejo","family":"Rodriguez-Vida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Isaacsson","family":"Velho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Nol\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe Melo","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry Andr\u00e9","family":"Roumegu\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gedske","family":"Daugaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosely","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Poncet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corneel","family":"Coens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0093-8408","authenticated-orcid":false,"given":"Bertrand F.","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.08.001_b0005","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.08.001_b0010","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","article-title":"Management of patients with advanced prostate cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.08.001_b0015","unstructured":"EAU guidelines. Edn. Presented at the EAU Annual Congress Paris 2024. EAU Guidelines Office, Arnhem, The Netherlands. ISBN 978-94-92671-23-3; 2024. http:\/\/uroweb.org\/guidelines\/compilations-of-all-guidelines\/."},{"key":"10.1016\/j.euo.2026.08.001_b0020","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.clgc.2019.12.019","article-title":"Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States","volume":"18","author":"George","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2026.08.001_b0025","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.annonc.2025.05.011","article-title":"Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333\/PEACE-3 trial","volume":"36","author":"Tombal","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2026.08.001_b0030","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.annonc.2026.02.009","article-title":"Final overall survival results from EORTC 1333\/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer","volume":"37","author":"Gillessen","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2026.08.001_b0035","unstructured":"European Medicines Agency. Xofigo - referral; 2018. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/xofigo."},{"key":"10.1016\/j.euo.2026.08.001_b0040","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.eururo.2024.11.027","article-title":"Decrease in fracture rate with mandatory bone-protecting agents in the EORTC 1333\/PEACE-3 trial comparing radium-223 combined with Enzalutamide versus Enzalutamide Alone: a safety analysis","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.08.001_b0045","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.urolonc.2010.07.002","article-title":"Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy","volume":"30","author":"Sonpavde","year":"2012","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2026.08.001_b0050","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.euo.2018.11.005","article-title":"Prognostic association of prostate-specific antigen decrease with clinical outcomes in men with metastatic castration-resistant prostate cancer treated with enzalutamide in a randomized clinical trial","volume":"2","author":"Armstrong","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.08.001_b0055","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/s41585-019-0251-x","article-title":"Radium-223 mechanism of action: implications for use in treatment combinations","volume":"16","author":"Morris","year":"2019","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2026.08.001_b0060","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.3390\/ijms20163899","article-title":"The mode-of-action of targeted alpha therapy radium-223 as an enabler for novel combinations to treat patients with bone metastasis","volume":"20","author":"Suominen","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.euo.2026.08.001_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101993","article-title":"Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer","volume":"60","author":"Higano","year":"2023","journal-title":"EClinicalmedicine"},{"key":"10.1016\/j.euo.2026.08.001_b0070","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.1158\/1078-0432.CCR-15-3086","article-title":"Changes in bone turnover marker levels and clinical outcomes in patients with advanced cancer and bone metastases treated with bone antiresorptive agents","volume":"22","author":"Lipton","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2026.08.001_b0075","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41416-024-02927-w","article-title":"Alkaline phosphatase decrease and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE study","volume":"132","author":"O'Sullivan","year":"2025","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euo.2026.08.001_b0080","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/annonc\/mdx044","article-title":"An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223","volume":"28","author":"Sartor","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2026.08.001_b0085","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1470-2045(07)70147-X","article-title":"Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study","volume":"8","author":"Nilsson","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.08.001_b0090","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41391-022-00622-6","article-title":"Prostate-specific antigen response and clinical progression-free survival in Black and White men with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide in a real-world setting","volume":"26","author":"Freedland","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2026.08.001_b0095","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.eururo.2020.04.061","article-title":"Five-year survival prediction and safety outcomes with enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer from the PREVAIL trial","volume":"78","author":"Armstrong","year":"2020","journal-title":"Eur Urol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126002282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126002282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T20:00:01Z","timestamp":1788033601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126002282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":19,"alternative-id":["S2588931126002282"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.08.001","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alkaline Phosphatase and Prostate-specific Antigen Response in Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide Alone or in Combination with Radium-223: Ad Hoc Analysis of the PEACE-3 Consortium Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}